Mizuho Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has maintained a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and increased the price target from $20 to $30.
December 07, 2023 | 5:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Buy rating on EyePoint Pharmaceuticals and raises the price target from $20 to $30.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance and can lead to increased investor confidence. This often results in a short-term uptick in the stock price as the market reacts to the new information.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100